James W. Antoon, Ph.D.
Affiliations: | 2010 | Pharmacology | Tulane University, New Orleans, LA, United States |
Area:
Pharmacology, Molecular Biology, Medicine and SurgeryGoogle:
"James Antoon"Parents
Sign in to add mentorBarbara S. Beckman | grad student | 2010 | Tulane | |
(The ceramide-sphingosine-1-phosphate rheostat as a therapeutic target in endocrine and chemotherapy resistant breast cancer.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Gestaut MM, Antoon JW, Burow ME, et al. (2014) Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacological Reports : Pr. 66: 174-8 |
Ponnapakam AP, Liu J, Bhinge KN, et al. (2014) 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. Bioorganic & Medicinal Chemistry. 22: 1412-20 |
Martin EC, Elliott S, Rhodes LV, et al. (2014) Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 53: 38-48 |
White MD, Chan L, Antoon JW, et al. (2013) Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Research. 33: 3573-9 |
Antoon JW, Martin EC, Lai R, et al. (2013) MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. Plos One. 8: e69291 |
Antoon JW, Nitzchke AM, Martin EC, et al. (2013) Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology. 42: 1139-50 |
Antoon JW, Bratton MR, Guillot LM, et al. (2012) Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. American Journal of Cancer Research. 2: 446-58 |
Antoon JW, White MD, Driver JL, et al. (2012) Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Experimental Biology and Medicine (Maywood, N.J.). 237: 832-44 |
Antoon JW, Lai R, Struckhoff AP, et al. (2012) Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific Reports. 2: 539 |
Antoon JW, Bratton MR, Guillot LM, et al. (2012) Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology & Therapy. 13: 1026-33 |